Key result
All 10 long-haul COVID-19 patients developed POTS during tilt testing and exhibited similar symptoms and more severe cerebral blood flow reductions compared to ME/CFS patients with normal responses.
Why the study?
Orthostatic symptoms and hemodynamic findings have been reported in long-haul COVID-19 and ME/CFS, but little work had directly compared patients from these two groups.
Do long-haul COVID-19 patients exhibit similar orthostatic symptoms and cerebral blood flow reductions during head-up tilt testing compared to ME/CFS patients?
Case-Control (n=60)
Do long-haul COVID-19 patients exhibit similar orthostatic symptoms and cerebral blood flow reductions during head-up tilt testing compared to ME/CFS patients?
Long-haul COVID-19 patients exhibit orthostatic intolerance, POTS, and cerebral blood flow reductions during tilt testing that closely resemble the pathophysiology of ME/CFS.
May indicate POTS with severe CBF reduction in long-haul COVID; leaves open generalizability and clinical implications.
Background and Objectives: Symptoms and hemodynamic findings during orthostatic stress have been reported in both long-haul COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), but little work has directly compared patients from these two groups. To investigate the overlap in these clinical phenotypes, we compared orthostatic symptoms in daily life and during head-up tilt, heart rate and blood pressure responses to tilt, and reductions in cerebral blood flow in response to orthostatic stress in long-haul COVID-19 patients, ME/CFS controls, and healthy controls. Materials and Methods: We compared 10 consecutive long-haul COVID-19 cases with 20 age- and gender-matched ME/CFS controls with postural tachycardia syndrome (POTS) during head-up tilt, 20 age- and gender-matched ME/CFS controls with a normal heart rate and blood pressure response to head-up tilt, and 10 age- and gender-matched healthy controls. Identical symptom questionnaires and tilt test procedures were used for all groups, including measurement of cerebral blood flow and cardiac index during the orthostatic stress. Results: There were no significant differences in ME/CFS symptom prevalence between the long-haul COVID-19 patients and the ME/CFS patients. All long-haul COVID-19 patients developed POTS during tilt. Cerebral blood flow and cardiac index were more significantly reduced in the three patient groups compared with the healthy controls. Cardiac index reduction was not different between the three patient groups. The cerebral blood flow reduction was larger in the long-haul COVID-19 patients compared with the ME/CFS patients with a normal heart rate and blood pressure response. Conclusions: The symptoms of long-haul COVID-19 are similar to those of ME/CFS patients, as is the response to tilt testing. Cerebral blood flow and cardiac index reductions during tilt were more severely impaired than in many patients with ME/CFS. The finding of early-onset orthostatic intolerance symptoms, and the high pre-illness physical activity level of the long-haul COVID-19 patients, makes it unlikely that POTS in this group is due to deconditioning. These data suggest that similar to SARS-CoV-1, SARS-CoV-2 infection acts as a trigger for the development of ME/CFS.
No takes yet. Share an insight, caveat, or question.
Campen et al. (2021) conducted a case-control in Long-haul COVID-19 and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (n=60). Long-haul COVID-19 vs. ME/CFS controls and healthy controls was evaluated on Orthostatic symptoms, heart rate and blood pressure responses to tilt, and reductions in cerebral blood flow. All 10 long-haul COVID-19 patients developed POTS during tilt testing and exhibited similar symptoms and more severe cerebral blood flow reductions compared to ME/CFS patients with normal responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: